INSYS Therapeutics, Inc. (INSY) Analysts See $-0.25 EPS

July 12, 2018 - By Lisa Delgado

Investors sentiment decreased to 0.75 in 2018 Q1. Its down 0.01, from 0.76 in 2017Q4. It turned negative, as 14 investors sold INSYS Therapeutics, Inc. shares while 30 reduced holdings. 11 funds opened positions while 22 raised stakes. 12.41 million shares or 24.49% less from 16.43 million shares in 2017Q4 were reported.
Schwab Charles Invest Mgmt has invested 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Qs Limited Liability Company has invested 0.01% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Sfmg owns 0.01% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 11,994 shares. State Of Wisconsin Board, Wisconsin-based fund reported 19,000 shares. Northern Tru Corporation holds 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 316,325 shares. Janney Montgomery Scott Ltd Limited Liability Company holds 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 39,284 shares. Alphamark Advsrs Ltd Liability Com has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 740 shares. Bnp Paribas Arbitrage Sa holds 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY) or 21,104 shares. Wells Fargo & Communication Mn holds 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 54,464 shares. 25,624 are owned by Jpmorgan Chase & Company. Deutsche Bancorporation Ag accumulated 0% or 76,616 shares. Royal National Bank Of Canada holds 0% or 32,874 shares in its portfolio. Tci Wealth Advisors holds 0.02% or 7,766 shares. Meeder Asset Mgmt reported 162 shares. Raymond James & Associates holds 0% or 18,233 shares.

Since February 21, 2018, it had 0 insider buys, and 1 insider sale for $1.07 million activity.

Analysts expect INSYS Therapeutics, Inc. (NASDAQ:INSY) to report $-0.25 EPS on August, 2.They anticipate $0.24 EPS change or 2,400.00 % from last quarter’s $-0.01 EPS. After having $-0.22 EPS previously, INSYS Therapeutics, Inc.’s analysts see 13.64 % EPS growth. The stock increased 0.53% or $0.04 during the last trading session, reaching $7.65. About 311,296 shares traded. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 47.95% since July 12, 2017 and is downtrending. It has underperformed by 60.52% the S&P500.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $564.64 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

More notable recent INSYS Therapeutics, Inc. (NASDAQ:INSY) news were published by: Nasdaq.com which released: “Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to …” on June 14, 2018, also Benzinga.com with their article: “5 Hot Pot Stocks In 2018 And 5 More To Watch The Rest Of The Year” published on July 10, 2018, Nasdaq.com published: “INSYS Therapeutics Provides an Update on Its Ongoing Transformation” on June 18, 2018. More interesting news about INSYS Therapeutics, Inc. (NASDAQ:INSY) were released by: Benzinga.com and their article: “A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year” published on July 05, 2018 as well as Investorplace.com‘s news article titled: “4 Drug and Biotech Stocks Awaiting FDA Decisions in July” with publication date: July 02, 2018.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.